"3-Iodobenzylguanidine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A guanidine analog with specific affinity for tissues of the sympathetic nervous system and related tumors. The radiolabeled forms are used as antineoplastic agents and radioactive imaging agents. (Merck Index, 12th ed) MIBG serves as a neuron-blocking agent which has a strong affinity for, and retention in, the adrenal medulla and also inhibits ADP-ribosyltransferase.
| Descriptor ID |
D019797
|
| MeSH Number(s) |
D02.078.370.510 D02.455.426.559.389.454.300 D02.455.526.581.496.300
|
| Concept/Terms |
3-Iodobenzylguanidine- 3-Iodobenzylguanidine
- 3 Iodobenzylguanidine
- MIBG
- meta-Iodobenzylguanidine
- meta Iodobenzylguanidine
- Iobenguane
- m-Iodobenzylguanidine
- m Iodobenzylguanidine
|
Below are MeSH descriptors whose meaning is more general than "3-Iodobenzylguanidine".
Below are MeSH descriptors whose meaning is more specific than "3-Iodobenzylguanidine".
This graph shows the total number of publications written about "3-Iodobenzylguanidine" by people in this website by year, and whether "3-Iodobenzylguanidine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "3-Iodobenzylguanidine" by people in Profiles.
-
The Experience of Children With Neuroblastoma and Their Parents During Single-Room Isolation for 131I-Metaiodobenzylguanidine Therapy: A Qualitative Descriptive Study. J Pediatr Hematol Oncol Nurs. 2022 Sep-Oct; 39(5):304-316.
-
Predicting Response to Chemotherapy in Patients With Newly Diagnosed High-Risk Neuroblastoma: A Report From the International Neuroblastoma Risk Group. JCO Clin Cancer Inform. 2021 12; 5:1181-1188.
-
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. J Clin Oncol. 2021 11 01; 39(31):3506-3514.
-
Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma. Pediatr Blood Cancer. 2018 12; 65(12):e27417.
-
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017 Aug 01; 35(22):2580-2587.
-
¹³¹I-Metaiodobenzylguanidine Theranostics in Neuroblastoma: Historical Perspectives; Practical Applications. Semin Nucl Med. 2016 May; 46(3):184-202.
-
Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG). Pediatr Blood Cancer. 2016 Mar; 63(3):436-42.
-
Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2015 Jun 15; 21(12):2715-21.
-
131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study. Biol Blood Marrow Transplant. 2015 Apr; 21(4):673-81.
-
Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group. J Nucl Med. 2013 Apr; 54(4):541-8.